-
2023-507889-89-00
5
2016-02-19
Respiratory tract infection
-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine
-
2024-511096-15-00
5
2014-08-01
Breast Cancer
-
2024-517622-25-00
5
2013-12-06
Patients with localized prostate cancer and high-risk features of rela
-
2024-516198-61-00
5
2013-06-05
Patients with high risk of relapse, ER+ and HER2- primary non-metastat
-
2024-516996-34-00
5
2012-04-12
oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
-
2023-505433-27-00
5
2024-08-13
Atopic Dermatitis
-
2023-509336-25-00
9
2024-06-12
Metastatic castration-resistant prostate cancer
-
2022-502453-33-00
4
2024-02-26
Advanced Endometrial Cancer
-
2022-500389-84-00
6
2024-02-16
Febrile neutropenia
-
2023-503356-27-00
4
2023-09-07
Metastatic colorectal cancer that is resistant to the currently approv
-
2023-508267-69-00
3
2023-08-11
Subjects with Aadvanced solid tumors for whom life-prolonging therapie
-
2023-509686-21-00
1
2023-07-05
Solid Tumors
-
2023-504869-23-00
11
2023-05-31
Dermatitis atopic
-
2022-501078-20-00
4
2023-05-15
Metastatic Castration-resistant Prostate Cancer
-
2022-501585-22-00
5
2023-05-11
Atopic Dermatitis
-
2022-501363-40-00
3
2023-03-17
Advanced or metastatic solid tumors with a KRAS-G12C mutation
-
2022-501183-17-00
7
2023-02-23
Non-Small Cell Lung Cancer
-
2023-503794-38-00
5
2022-11-24
Prevention of stroke or systemic embolism in atrial fibrillation
-
2024-514714-12-00
10
2022-11-11
Metastatic Pancreatic Ductal Adenocarcinoma
-
2023-505458-16-00
5
2022-09-13
Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
-
2024-513559-34-00
5
2022-07-19
Small Cell Lung Cancer (SCLC)
-
2023-505455-44-00
9
2022-06-29
Solid tumours
-
2023-509668-11-00
6
2022-06-15
Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.